Juvenile Idiopathic Arthritis
📧 Sign up to get email alerts when something new happens for Juvenile Idiopathic Arthritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-08-02Clinical Trial Update: Etanercept Plus Methotrexate Versus Methotrexate Alone in Children With Polyarticular Course Juvenile Rheumatoid Arthritis [Phase 3]
Phase 3 trial comparing etanercept plus methotrexate versus methotrexate alone in children with polyarticular-course juvenile rheumatoid art…
-
FDA approval · 2019-07-25FDA Approved: XELJANZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA entry describing a supplemental application for XELJANZ (tofacitinib) submitted by Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2019-07-25FDA Approved: CELECOXIB — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for celecoxib from Apotex Corp., granting approval for a generic version of the product.
-
FDA approval · 2019-07-25FDA Approved: CELECOXIB — Supplemental Application (Aurobindo Pharma Limited)
FDA approves Aurobindo Pharma Limited's supplemental application for Celecoxib (generic Celecoxib), confirming the generic's approval. Celec…
-
FDA approval · 2019-07-25FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ XR (tofacitinib extended-release), expanding its formulation under Pfizer's submission.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-07-23FDA Approved: HADLIMA — Original Application (Organon LLC)
FDA approves Hadlima (adalimumab-bwwd) from Organon as a biosimilar to Humira under the original application BLA761059. It is indicated for …
-
FDA approval · 2019-07-22FDA Approved: IBUPROFEN — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approved Amneal Pharmaceuticals of New York LLC's supplemental application for a generic ibuprofen product. The approval confirms the ge…
-
FDA approval · 2019-03-21FDA Approved: ORENCIA — Supplemental Application (E.R. Squibb & Sons, L.L.C.)
FDA approved a supplemental application for ORENCIA (abatacept) submitted by E.R. Squibb & Sons, L.L.C., indicating a labeling change and/or…
-
EMA withdrawal · 2019-03-06EMA Withdrawn: Cyltezo (adalimumab) — Boehringer Ingelheim International GmbH
The EMA withdrew Cyltezo (adalimumab) from Boehringer Ingelheim International GmbH, affecting multiple indications including hidradenitis su…
-
CLINICAL_TRIALS research · 2019-02-07Clinical Trial Update: Yoga and Aerobic Dance for Pain Management in Juvenile Idiopathic Arthritis [NA]
This clinical trial update describes a study evaluating yoga and aerobic dance for pain management in Juvenile Idiopathic Arthritis; the tri…
-
FDA approval · 2018-10-30FDA Approved: ADALIMUMAB — Original Application (Sandoz Inc)
FDA approved the original application for the adalimumab biosimilar ADALIMUMAB-ADAZ from Sandoz Inc. The approval covers the same indication…
-
FDA approval · 2018-10-16FDA Approved: HUMIRA — Supplemental Application (Cordavis Limited)
FDA approved a supplemental application for Humira (adalimumab) submitted by Cordavis Limited.
-
FDA approval · 2018-10-03FDA Approved: ENBREL — Supplemental Application (Immunex Corporation)
FDA approved a supplemental application for Enbrel (etanercept) submitted by Immunex Corporation. The approval updates the labeling as descr…
-
CLINICAL_TRIALS research · 2018-07-23Clinical Trial Update: Fertility Study of Women With Chronic Inflammatory Rheumatism
This clinical trial update describes a fertility study in women with chronic inflammatory rheumatism, including psoriatic arthritis, rheumat…
-
CLINICAL_TRIALS trial_result · 2018-07-12Clinical Trial Update: Therapeutic Alliance is it Associated With Better Compliance Amongst Children With Juvenile Idiopathic Arthritis ?
A completed clinical trial explored whether a stronger therapeutic alliance is associated with better treatment adherence in children with J…
-
FDA approval · 2018-05-25FDA Approved: ENBREL — Supplemental Application (Immunex Corporation)
FDA approved a supplemental application for ENBREL (etanercept) submitted by Immunex Corporation. The approval pertains to the supplement to…
-
CLINICAL_TRIALS withdrawal · 2018-05-14Clinical Trial Update: Effect of Whole Body Vibration Therapy in Children With Juvenile Idiopathic Arthritis [NA]
A clinical trial assessing whole body vibration therapy in children with Juvenile Idiopathic Arthritis has been withdrawn.
-
FDA approval · 2018-05-11FDA Approved: ENBREL — Supplemental Application (Immunex Corporation)
The FDA approved a supplemental application for ENBREL (etanercept) submitted by Immunex Corporation. The action updates the drug's labeling…
-
CLINICAL_TRIALS trial_result · 2018-05-02Clinical Trial Update: Juvenile Arthritis Quantitative Imaging
Clinical trial update from University College London Hospitals on a quantitative imaging study for juvenile arthritis, including juvenile id…
-
FDA approval · 2018-04-30FDA Approved: CELECOXIB — Original Application (Micro Labs Limited)
FDA approved the original generic application for celecoxib from Micro Labs Limited, providing a generic celecoxib option aligned with the r…
-
CLINICAL_TRIALS trial_result · 2018-04-12Clinical Trial Update: Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease [Phase 2, Phase 3]
The Phase 2/3 trial evaluating growth hormone in children with Juvenile idiopathic arthritis and Crohn's disease was terminated, and results…
-
CLINICAL_TRIALS research · 2018-04-05Clinical Trial Update: Exercise and Body Composition in Juvenile Idiopathic Arthritis [NA]
This entry notes the completion of a Johns Hopkins University-sponsored clinical trial evaluating exercise and body composition in juvenile …
-
CLINICAL_TRIALS trial_result · 2018-03-29Clinical Trial Update: Human Factors Study of Methotrexate Prefilled Pen (50 mg/mL) in Patients With Juvenile Idiopathic Arthritis [EARLY_Phase 1]
Completed human factors study evaluating a Methotrexate prefilled pen (50 mg/mL) for administering methotrexate in Juvenile Idiopathic Arthr…
-
FDA approval · 2018-03-15FDA Approved: AMJEVITA — Supplemental Application (Nuvaila Limited)
FDA approved a supplemental application for AMJEVITA (adalimumab-atto) submitted by Nuvaila Limited.
-
CLINICAL_TRIALS research · 2018-03-05Clinical Trial Update: Pharmacovigilance in Juvenile Idiopathic Arthritis Patients Treated With Biologic Agents and/or Methotrexate
A clinical trial update describing pharmacovigilance activities in Juvenile Idiopathic Arthritis patients treated with biologic agents and/o…